GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Cyclically Adjusted Price-to-FCF

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pathfinder Cell Therapy Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Cyclically Adjusted Price-to-FCF Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF falls into.



Pathfinder Cell Therapy Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pathfinder Cell Therapy's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2015 is calculated as:

For example, Pathfinder Cell Therapy's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2015 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0/100.3915*100.3915
=0.000

Current CPI (Sep. 2015) = 100.3915.

Pathfinder Cell Therapy Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200512 -0.003 83.032 -0.004
200603 -0.009 84.298 -0.011
200606 -0.014 85.606 -0.016
200609 -0.009 85.606 -0.011
200612 -0.002 85.142 -0.002
200703 -0.013 86.640 -0.015
200706 -0.015 87.906 -0.017
200709 -0.010 87.964 -0.011
200712 -0.006 88.616 -0.007
200803 -0.015 90.090 -0.017
200806 -0.011 92.320 -0.012
200809 -0.009 92.307 -0.010
200812 -0.008 88.697 -0.009
200903 -0.010 89.744 -0.011
200906 -0.010 91.003 -0.011
200909 -0.008 91.120 -0.009
200912 -0.007 91.111 -0.008
201003 -0.002 91.821 -0.002
201006 -0.004 91.962 -0.004
201009 0.000 92.162 0.000
201012 -0.001 92.474 -0.001
201103 -0.001 94.283 -0.001
201106 -0.001 95.235 -0.001
201109 -0.002 95.727 -0.002
201112 -0.001 95.213 -0.001
201203 -0.001 96.783 -0.001
201206 -0.001 96.819 -0.001
201209 0.000 97.633 0.000
201212 -0.001 96.871 -0.001
201303 0.000 98.209 0.000
201306 -0.001 98.518 -0.001
201309 -0.001 98.790 -0.001
201312 -0.001 98.326 -0.001
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pathfinder Cell Therapy  (OTCPK:PFND) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pathfinder Cell Therapy Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines